Prelude therapeutics announces second quarter 2023 financial results and provides corporate update

Four lead programs on track to deliver clinical data and to inform future development plans recent equity financing extends cash runway into 2026,  enabling advancement of prelude's pipeline through critical milestones wilmington, del., aug. 03, 2023 (globe newswire) -- prelude therapeutics incorporated (nasdaq: prld), a clinical-stage precision oncology company, today reported financial results for the second quarter ended june 30, 2023, and provided a corporate update.
PRLD Ratings Summary
PRLD Quant Ranking